https://interhospi.com/wp-content/uploads/sites/3/2021/01/4_GREINER_BIO-ONE.jpg144710003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00We take care of your safety
HelpMeSee, a not-for-profit global campaign to end cataract blindness, has introduced an Eye Surgery Simulator, representing a landmark achievement in medical simulation training.
Equipped with sensory touch feedback and realistic virtual graphics, the HelpMeSee Eye Surgery Simulator, incorporated within the HelpMeSee Training Program, supports the training of cataract specialists on the Manual Small Incision Cataract Surgery (MSICS) procedure, a solution that could help end the global cataract blindness crisis.
Saro Jahani, HelpMeSee President and CEO, commented: “The HelpMeSee Eye Surgery Simulator overcomes the traditional restraints of cataract surgery training with unlimited virtual practice opportunities. It also offers the benefits of remote simulation-based training during the COVID-19 pandemic, limiting the risks of exposure to coronavirus infection.”
The HelpMeSee Eye Surgery Simulator encompasses an adaptation of an actual virtual microscope used in surgery, two haptic handpieces, a virtual syringe, the patient head and hand rest, and a touchscreen user interface, powerful visuals and simulation software, and everything required to simulate an MSICS surgery. The two handpieces and syringe represent the complete set of surgical instruments needed to perform an MSICS procedure. Programmed lessons with onscreen guides and error messages assist the student in mastering the MSICS technique and the instructor in providing objective feedback.
More than 60 million people across the world are blind or severely visually impaired simply because they cannot access cataract surgery, according to the World Health Organization (WHO) and the International Association for the Prevention of Blindness (IAPB). The HelpMeSee Simulator and training program along with partners can develop a significant number of cataract specialists that public health experts say are needed to address the developing world ophthalmologist shortage, a factor behind the cataract surgery backlog.
The simulator was the innovative vision of Flight Safety International Founder Albert L. Ueltschi and his son, James "Jim" Tyler Ueltschi. In 2010, they founded HelpMeSee to end the backlog of cataract and visual impairment cases caused by the lack of access to high-quality, affordable cataract surgery.
Jim Ueltschi, Co-Founder and Chairman of HelpMeSee, said: “This achievement will truly change the world of ophthalmology. Every specialist we train on the Eye Surgery Simulator will treat thousands of people each year. Over time, millions will have their vision restored through the cataract surgery skills honed on the HelpMeSee Simulator.”
Siemens Healthineers showed their new fluoroscopy system, the Luminos Lotus Max, at the annual French JFR 2020 in early October. The system offers advanced technology in radiography and fluoroscopy.
The remote-controlled Luminos Lotus Max system offers versatility in clinical examinations by combining radiographic and fluoroscopic imaging with orthopedic studies such as long leg or spinal examinations and basic interventions. Users can quickly switch between the different imaging modalities because they are integrated.
Commenting on the new fluoroscopy system, Carsten Bertram, Head of Business Line X-ray Products, said: “Combining these state-of-the-art technologies poses one major challenge: ensuring efficient workflows and high system utilization. With our new device, healthcare professionals now benefit from a new level of integration for ‘uninterrupted flow‘ in radiographic and fluoroscopic exams. It’s all on one system and in one room.”
The Luminos Lotus Max also features automation aimed at ensuring ease of use and patient safety. This automation helps technicians apply the optimal radiation dose for each patient and examination type without compromising clinical results. Accordong to Siemens Healthineers, the device automatically encrypts all images and patient data. Combined with regular software updates to prevent new risks and an elaborate role-based access control, this ensures that the highest cybersecurity standards are met. Read more
https://interhospi.com/wp-content/uploads/sites/3/2021/01/11_PRODUCT_SIEMENS.jpg65810003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00Siemens Healthineers introduces new fluoroscopy system
Fujifilm Sonosite has recently introduced the new Sonosite PX ultrasound system – a next generation point-of-care ultrasound with the most advanced image clarity ever seen in a Sonosite system, a suite of workflow efficiency features, and an adaptable form factor. Rich Fabian, President and CEO of Fujifilm Sonosite said: “Every aspect of Sonosite PX was designed specifically for the clinicians on the front lines of medicine. We designed Sonosite PX as a tool to help clinicians in all fields of medicine to treat patients more effectively where it matters most – at the point of care.
“To optimize clinician ergonomics and improve efficiency, the system has an innovative and adaptable work surface that can be used in a horizontal or vertical position based on the situational needs of the exam. The exceptional image clarity is the result of a new proprietary imaging technology – seeing anatomy more clearly with Sonosite PX provides an unparalleled level of confidence for diagnostic and procedural applications.”
The ultrasound system and the new family of transducers are drop-tested to one meter and the work surface is sealed to the edge for simplified cleaning and disinfection. When mounted on the specialized stand, Sonosite PX has an adaptable work surface position for optimal clinician ergonomics while a small footprint and adjustable height allows for closer bedside access.
Information essential to completing an exam including patient information, reports, and worksheets, is intuitively placed in one location, saving clinicians time and effort when navigating the ultrasound system user interface.
Diku Mandavia, MD, FACEP, FRCPC, Senior Vice President and Chief Medical Officer of Fujifilm Sonosite, said: “The system has two cardiac options that allow clinicians to choose between gathering targeted information about the heart to determine overall patient well-being, or investigate specific cardiac conditions with more comprehensive calculations that provide detailed analysis of the structure and function of the heart. This allows clinicians to select the cardiac exam type that best fits their individual workflow needs.
“Furthermore in keeping with our commitment to education, we have greatly expanded our 3D animation educational videos which are very important to new users. Sonosite PX has more than 100 onboard scan-along education tutorials; the most expansive library in any point-of-care system.”
Sonosite PX has been designed for onboard documentation of ultrasound findings at the bedside which assists in the efficient documentation to the electronic medical record.
For more information, visit: www.sonosite.com Read more
https://interhospi.com/wp-content/uploads/sites/3/2021/01/9_PRODUCT_FUJIFILM.jpg64910003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00Fujifilm Sonosite introduces Sonosite PX ultrasound system
Telemis, the medical imaging, archiving and transmission specialist, has released a new version of the company’s widely-deployed Telemis-Medical platform. The company says that through the tech advances within Telemis-Medical Version 4.95, physicians will be able to perform functions much quicker – leading to considerable time savings and greater convenience.
The latest version of Telemis-Medical expands the array of possible configurations of diagnostic media (DICOM images, JPG and PDF files, videos, etc.) accelerating access, analysis, and sharing of vital data.
Among the major add-ons is access to an unlimited choice of user-defined mouse button combinations, which will speed up the image manipulation process. Users will also benefit from a swift and intuitive drag-and-drop tool that facilitates export of images to multiple destinations.
In relation to the treatment of cancer patients, specifically radiotherapy, this latest upgrade also offers new features. For example, with the help of the improved Dose Volume Histograms (DVHs), radiotherapists will be able to monitor radiation intensity and localization better.
In addition, the new version of Telemis-Medical has substantially bolstered security mechanisms in order to safeguard patient data. URLs randomization adds a level of security to the image distribution platform (TM-Publisher Web) in full compliance with the General Data Protection Regulation (GDPR) guidelines. Furthermore, healthcare institutions can define their own ‘conditions of use’, which TM-Publisher Web users will be asked to accept before accessing any data.
For more information, visit: www.telemis.com Read more
https://interhospi.com/wp-content/uploads/sites/3/2021/01/8_PRODUCT_TELEMIS.jpg48210003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00Telemis releases new version of its medical platform
The VeinViewer® from Greiner Bio-One helps doctors and healthcare workers with venous access for venipunture by providing a visualization of the veins beneath the skin.
The VeinViewer uses harmless near-infrared (NIR) light which is absorbed by haemoglobin in the blood and surrounding tissue and reflected back to the VeinViewer device, where the data is processed into an image; colour is added and the image is reflected back to the skin surface to provide a real time visualization of the blood vessels and patterns up to 10 mm below the skin. High Definition technology helps provide the clinician with clear, sharp imaging to support routine healthcare work when vein conditions are poor. Two devices are available: VeinViewer Flex and VeinViewer Vision2 VeinViewer Flex is a portable device for use in emergency situations or in rooms with limited space. The VeinViewer Flex can be made static by using the flexible arm provided for attachment to a table or arm of a chair, for example.
The VeinViewer Vision2 is a mobile imaging unit with an arm reaching up to 135 cm. The VeinViewer Vision2 is attached to a trolley for easy transportation between beds or phlebotomy chairs.
VeinViewer is recommended for many application areas:
Vein care centres – spider veins
Oncology
Geriatrics
Dialysis wards
Casualty / emergency situations, triage
Paediatrics
Neonatology
Doctors’ offices
For more information, visit: www.gbo.com Read more
https://interhospi.com/wp-content/uploads/sites/3/2021/01/6_PRODUCT_VEINVIEWER.jpg6426963wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00VeinViewer makes veins visible
Biotech scientists have developed a new polymeric heart valve, called the PoliValve, with a life span potentially longer than current artificial valves.
The PoliValve will also prevent the need for the millions of patients with diseased heart valves to require life-long blood thinning medication.
There are two artificial valves currently available for patients with diseased heart valves; both have limitations either in durability or in biocompatibility. Biological valves are made from fixed pig or cow tissue and have good biocompatibility, but limitations in durability of 10 to 15 years. Mechanical valves have very good durability, but poor biocompatibility and patients must take daily blood thinning drugs to prevent blood clots.
The PoliValve, created by Prof. Geoff Moggridge, Dr Marta Serrani and Dr Joanna Stasiak at Cambridge’s Department of Chemical Engineering and Biotechnology, and Prof. Raimondo Ascione, Head of the Translational Biomedical Research Centre (TBRC) at the University of Bristol, is made from a special co-polymer and is designed to resemble the flexibility, biocompatibility and durability of a natural heart valve. They have spent three years conducting developmental work and extra-vivo and in-vivo testing on the new PoliValve.
The device combines excellent durability with biocompatibility, addressing the limitations of current biological and mechanical artificial valves. It is made through a simple moulding process; hence it also reduces markedly manufacture and quality control costs.
Initial testing in animal has been undertaken at Bristol’s TBRC facility as a first mandatory in-vivo testing step to ensure safety. Long-term in-vivo testing is already planned and funded as a necessary additional step before bringing it to market.
According to the ISO standards a new artificial heart valve must withstand a minimum of 200 million repetitions of opening and closing during bench testing (equivalent to five-year life span) to be tested in humans. The new Cambridge- Bristol polymeric valve has comfortably surpassed this.
Prof. Ascione noted: “The transformational PoliValve results from an advanced Bristol/ Cambridge-based biomedical cross-fertilisation between experts in biomaterials, computational modelling, advanced preclinical development/ testing and clinical academics understanding the patient needs. The new valve could help millions of people worldwide and we aim to test in patients within the next five years.” Read more
https://interhospi.com/wp-content/uploads/sites/3/2021/01/5_PRODUCT_BIOTECH.jpg6016963wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-12-23 00:00:002023-09-06 08:31:36Scientists develop new heart valve with improved biocompatibility and durability
Philips has introduced OmniWire, the world’s first solid core pressure wire for coronary artery interventional procedures.
Its breakthrough solid core construction enables physicians to more easily manoeuvre the wire in the patient’s circulatory system to measure blood pressure along the vessel and guide the delivery of catheters and stents.
The new wire supports iFR (instant wave-Free Ratio) measurements, the only resting index supported by randomized controlled outcome trials, as well as FFR (fractional flow reserve) measurements. It also integrates with the Philips IntraSight interventional applications platform, which can co-register iFR data onto the angiogram to precisely identify the parts of vessels requiring treatment.
Traditional pressure wires use a hollow metal tube (hypotube) to house the wiring that transmits the pressure information. Due to their thin walls, these wires can be challenging to manoeuvre and can sometimes kink, potentially becoming damaged during the procedure. OmniWire is the world’s first solid core pressure guidewire, using advanced conductive ribbons embedded in its outer polymer layer to communicate pressure information. The distal part of the wire is made from Nitinol, a super-elastic, durable material that is commonly used in non-diagnostic, interventional ‘workhorse’ guide wires. The proximal part of the wire is constructed from a highstrength cobalt alloy that provides the high durability required for complex and multi-vessel cases.
Commenting on the device, Dr. Jasvindar Singh, director of the catheterization lab at Barnes Jewish Hospital and associate professor at Washington University in St. Louis, U.S., who performed the first human case with OmniWire in the United States, said: “I have been very impressed with the handling of OmniWire, the new solid core design performed beautifully, and I was able to navigate the difficult case easily. We used iFR co-registration and found that the patient needed a stent. I was then able to perform the whole procedure working over OmniWire. This is truly an innovation in percutaneous coronary interventions.”
OmniWire has received clearance from the U.S. FDA and approval from the Japan Pharmaceuticals and Medical Devices Agency. Read more
https://interhospi.com/wp-content/uploads/sites/3/2021/01/4_PRODUCT_PHILIPS.jpg6288003wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00Philips introduces OmniWire, the world’s first solid core pressure guide wire for coronary artery interventional procedures
Materials scientists from Nanyang Technological University, Singapore have invented a new type of surgical glue that can bond blood vessels and close wounds, even when their surfaces are wet.
Named CaproGlu, it is activated by a low dose of ultraviolet light that cures it in seconds, turning it from a liquid glue into a solid but flexible biorubber – a biocompatible material that can be resorbed by the tissue after a few weeks.
Unlike current bio-adhesives – which need two chemicals to be mixed prior to use – the CaproGlu is a one-pot liquid gel solution that comes ready-to-use.
In a study published in Biomaterials in July they showed in animal experiments that blood vessels can be rejoined with just four stitches and a mesh wrapper dipped in CaproGlu, compared to the usual eight stitches that are required for a reliable and unobstructed join. The authors estimate that this will reduce surgery time by 25 per cent, as surgeons spend less time and effort stitching up blood vessels and tissues.
They also showed that CaproGlu can also be used to deliver local anaesthetics or pain relief medication to tissues in the body, which may be useful both during and post operation.
The adhesion strength of CaproGlu was compared to other commercial bioadhesives on the market and was found to be three to seven times stronger, and is on a par with the shear strength of collagen and muscle tissue found in the human body.
CaproGlu combines two ingredients into a single-component formulation that does not require additives. The first is polycaprolactone – a biodegradable polymer which has been approved by the United States Food and Drug Administration for specific applications used in the human body – and the second: diazirine, a light-sensitive molecule that can form strong bonds when activated.
The research team have filed for a provisional patent for the biorubber glue. Read more
https://interhospi.com/wp-content/uploads/sites/3/2021/01/2_PRODUCT_CAPROGLU_1.jpg4736653wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00New biorubber glue can bond blood vessels, close wounds
Biotronik has introduced a new injectable cardiac monitor (ICM). The BIOMONITOR IIIm is equipped with a unique algorithm that significantly reduces false positive atrial fibrillation (AF) detections due to ectopic beats.
Physicians can lose time reviewing these nonactionable episodes. Research shows that 52% of false positive AF episodes occur due to premature ectopic beats, which can be falsely detected as AF.
According to Biotronik, the new device can achieve a 72% reduction in false positives while maintaining 100% of AF-related sensitivity. It removes single ectopic beats out of the AF detection algorithm, enhancing diagnostic accuracy. This will make physicians’ workload more efficient.
These new features are supported by image quality comparable to those recorded on a gold-standard 12-lead ECG.
BIOMONITOR IIIm is also the industry leader in battery longevity with 5.5 years of continuous service, providing long-term post-ablation or cryptogenic stroke monitoring. It is also backed by the Patient App, which allows patients to include vital symptom data, providing physicians with symptom-rhythm correlation which strengthens diagnostic precision.
For more information, visit: www.biotronik.com/en-de/products/arrhythmiamonitoring/ biomonitorIIIm Read more
https://interhospi.com/wp-content/uploads/sites/3/2021/01/1_PRODUCT_BIOTRONIK.jpg6217913wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2020-12-23 00:00:002020-12-23 00:00:00Biotronik’s a new injectable cardiac monitor reduces false positive readings
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
We take care of your safety
, /in Featured Articles /by 3wmediaNeedlestick injuries are history
HelpMeSee launches ground-breaking Eye Surgery Simulator
, /in Product News /by 3wmediaHelpMeSee, a not-for-profit global campaign to end cataract blindness, has introduced an Eye Surgery Simulator, representing a landmark achievement in medical simulation training.
Equipped with sensory touch feedback and realistic virtual graphics, the HelpMeSee Eye Surgery Simulator, incorporated within the HelpMeSee Training Program, supports the training of cataract specialists on the Manual Small Incision Cataract Surgery (MSICS) procedure, a solution that could help end the global cataract blindness crisis.
Saro Jahani, HelpMeSee President and CEO, commented: “The HelpMeSee Eye Surgery Simulator overcomes the traditional restraints of cataract surgery training with unlimited virtual practice opportunities. It also offers the benefits of remote simulation-based training during the COVID-19 pandemic, limiting the risks of exposure to coronavirus infection.”
The HelpMeSee Eye Surgery Simulator encompasses an adaptation of an actual virtual microscope used in surgery, two haptic handpieces, a virtual syringe, the patient head and hand rest, and a touchscreen user interface, powerful visuals and simulation software, and everything required to simulate an MSICS surgery. The two handpieces and syringe represent the complete set of surgical instruments needed to perform an MSICS procedure. Programmed lessons with onscreen guides and error messages assist the student in mastering the MSICS technique and the instructor in providing objective feedback.
More than 60 million people across the world are blind or severely visually impaired simply because they cannot access cataract surgery, according to the World Health Organization (WHO) and the International Association for the Prevention of Blindness (IAPB). The HelpMeSee Simulator and training program along with partners can develop a significant number of cataract specialists that public health experts say are needed to address the developing world ophthalmologist shortage, a factor behind the cataract surgery backlog.
The simulator was the innovative vision of Flight Safety International Founder Albert L. Ueltschi and his son, James "Jim" Tyler Ueltschi. In 2010, they founded HelpMeSee to end the backlog of cataract and visual impairment cases caused by the lack of access to high-quality, affordable cataract surgery.
Jim Ueltschi, Co-Founder and Chairman of HelpMeSee, said: “This achievement will truly change the world of ophthalmology. Every specialist we train on the Eye Surgery Simulator will treat thousands of people each year. Over time, millions will have their vision restored through the cataract surgery skills honed on the HelpMeSee Simulator.”
Read more
Siemens Healthineers introduces new fluoroscopy system
, /in Product News /by 3wmediaSiemens Healthineers showed their new fluoroscopy system, the Luminos Lotus Max, at the annual French JFR 2020 in early October. The system offers advanced technology in radiography and fluoroscopy.
The remote-controlled Luminos Lotus Max system offers versatility in clinical examinations by combining radiographic and fluoroscopic imaging with orthopedic studies such as long leg or spinal examinations and basic interventions. Users can quickly switch between the different imaging modalities because they are integrated.
Commenting on the new fluoroscopy system, Carsten Bertram, Head of Business Line X-ray Products, said: “Combining these state-of-the-art technologies poses one major challenge: ensuring efficient workflows and high system utilization. With our new device, healthcare professionals now benefit from a new level of integration for ‘uninterrupted flow‘ in radiographic and fluoroscopic exams. It’s all on one system and in one room.”
The Luminos Lotus Max also features automation aimed at ensuring ease of use and patient safety. This automation helps technicians apply the optimal radiation dose for each patient and examination type without compromising clinical results. Accordong to Siemens Healthineers, the device automatically encrypts all images and patient data. Combined with regular software updates to prevent new risks and an elaborate role-based access control, this ensures that the highest cybersecurity standards are met.
Read more
Fujifilm Sonosite introduces Sonosite PX ultrasound system
, /in Product News /by 3wmediaFujifilm Sonosite has recently introduced the new Sonosite PX ultrasound system – a next generation point-of-care ultrasound with the most advanced image clarity ever seen in a Sonosite system, a suite of workflow efficiency features, and an adaptable form factor. Rich Fabian, President and CEO of Fujifilm Sonosite said: “Every aspect of Sonosite PX was designed specifically for the clinicians on the front lines of medicine. We designed Sonosite PX as a tool to help clinicians in all fields of medicine to treat patients more effectively where it matters most – at the point of care.
“To optimize clinician ergonomics and improve efficiency, the system has an innovative and adaptable work surface that can be used in a horizontal or vertical position based on the situational needs of the exam. The exceptional image clarity is the result of a new proprietary imaging technology – seeing anatomy more clearly with Sonosite PX provides an unparalleled level of confidence for diagnostic and procedural applications.”
The ultrasound system and the new family of transducers are drop-tested to one meter and the work surface is sealed to the edge for simplified cleaning and disinfection. When mounted on the specialized stand, Sonosite PX has an adaptable work surface position for optimal clinician ergonomics while a small footprint and adjustable height allows for closer bedside access.
Information essential to completing an exam including patient information, reports, and worksheets, is intuitively placed in one location, saving clinicians time and effort when navigating the ultrasound system user interface.
Diku Mandavia, MD, FACEP, FRCPC, Senior Vice President and Chief Medical Officer of Fujifilm Sonosite, said: “The system has two cardiac options that allow clinicians to choose between gathering targeted information about the heart to determine overall patient well-being, or investigate specific cardiac conditions with more comprehensive calculations that provide detailed analysis of the structure and function of the heart. This allows clinicians to select the cardiac exam type that best fits their individual workflow needs.
“Furthermore in keeping with our commitment to education, we have greatly expanded our 3D animation educational videos which are very important to new users. Sonosite PX has more than 100 onboard scan-along education tutorials; the most expansive library in any point-of-care system.”
Sonosite PX has been designed for onboard documentation of ultrasound findings at the bedside which assists in the efficient documentation to the electronic medical record.
For more information, visit: www.sonosite.com
Read more
Telemis releases new version of its medical platform
, /in Product News /by 3wmediaTelemis, the medical imaging, archiving and transmission specialist, has released a new version of the company’s widely-deployed Telemis-Medical platform. The company says that through the tech advances within Telemis-Medical Version 4.95, physicians will be able to perform functions much quicker – leading to considerable time savings and greater convenience.
The latest version of Telemis-Medical expands the array of possible configurations of diagnostic media (DICOM images, JPG and PDF files, videos, etc.) accelerating access, analysis, and sharing of vital data.
Among the major add-ons is access to an unlimited choice of user-defined mouse button combinations, which will speed up the image manipulation process. Users will also benefit from a swift and intuitive drag-and-drop tool that facilitates export of images to multiple destinations.
In relation to the treatment of cancer patients, specifically radiotherapy, this latest upgrade also offers new features. For example, with the help of the improved Dose Volume Histograms (DVHs), radiotherapists will be able to monitor radiation intensity and localization better.
In addition, the new version of Telemis-Medical has substantially bolstered security mechanisms in order to safeguard patient data. URLs randomization adds a level of security to the image distribution platform (TM-Publisher Web) in full compliance with the General Data Protection Regulation (GDPR) guidelines. Furthermore, healthcare institutions can define their own ‘conditions of use’, which TM-Publisher Web users will be asked to accept before accessing any data.
For more information, visit: www.telemis.com
Read more
VeinViewer makes veins visible
, /in Product News /by 3wmediaThe VeinViewer® from Greiner Bio-One helps doctors and healthcare workers with venous access for venipunture by providing a visualization of the veins beneath the skin.
The VeinViewer uses harmless near-infrared (NIR) light which is absorbed by haemoglobin in the blood and surrounding tissue and reflected back to the VeinViewer device, where the data is processed into an image; colour is added and the image is reflected back to the skin surface to provide a real time visualization of the blood vessels and patterns up to 10 mm below the skin. High Definition technology helps provide the clinician with clear, sharp imaging to support routine healthcare work when vein conditions are poor.
Two devices are available: VeinViewer Flex and VeinViewer Vision2
VeinViewer Flex is a portable device for use in emergency situations or in rooms with limited space. The VeinViewer Flex can be made static by using the flexible arm provided for attachment to a table or arm of a chair, for example.
The VeinViewer Vision2 is a mobile imaging unit with an arm reaching up to 135 cm. The VeinViewer Vision2 is attached to a trolley for easy transportation between beds or phlebotomy chairs.
VeinViewer is recommended for many application areas:
For more information, visit: www.gbo.com
Read more
Scientists develop new heart valve with improved biocompatibility and durability
Cardiology, /in Product News /by 3wmediaBiotech scientists have developed a new polymeric heart valve, called the PoliValve, with a life span potentially longer than current artificial valves.
The PoliValve will also prevent the need for the millions of patients with diseased heart valves to require life-long blood thinning medication.
There are two artificial valves currently available for patients with diseased heart valves; both have limitations either in durability or in biocompatibility. Biological valves are made from fixed pig or cow tissue and have good biocompatibility, but limitations in durability of 10 to 15 years. Mechanical valves have very good durability, but poor biocompatibility and patients must take daily blood thinning drugs to prevent blood clots.
The PoliValve, created by Prof. Geoff Moggridge, Dr Marta Serrani and Dr Joanna Stasiak at Cambridge’s Department of Chemical Engineering and Biotechnology, and Prof. Raimondo Ascione, Head of the Translational Biomedical Research Centre (TBRC) at the University of Bristol, is made from a special co-polymer and is designed to resemble the flexibility, biocompatibility and durability of a natural heart valve. They have spent three years conducting developmental work and extra-vivo and in-vivo testing on the new PoliValve.
The device combines excellent durability with biocompatibility, addressing the limitations of current biological and mechanical artificial valves. It is made through a simple moulding process; hence it also reduces markedly manufacture and quality control costs.
Initial testing in animal has been undertaken at Bristol’s TBRC facility as a first mandatory in-vivo testing step to ensure safety. Long-term in-vivo testing is already planned and funded as a necessary additional step before bringing it to market.
According to the ISO standards a new artificial heart valve must withstand a minimum of 200 million repetitions of opening and closing during bench testing (equivalent to five-year life span) to be tested in humans. The new Cambridge- Bristol polymeric valve has comfortably surpassed this.
Prof. Ascione noted: “The transformational PoliValve results from an advanced Bristol/ Cambridge-based biomedical cross-fertilisation between experts in biomaterials, computational modelling, advanced preclinical development/ testing and clinical academics understanding the patient needs. The new valve could help millions of people worldwide and we aim to test in patients within the next five years.”
Read more
Philips introduces OmniWire, the world’s first solid core pressure guide wire for coronary artery interventional procedures
, /in Product News /by 3wmediaPhilips has introduced OmniWire, the world’s first solid core pressure wire for coronary artery interventional procedures.
Its breakthrough solid core construction enables physicians to more easily manoeuvre the wire in the patient’s circulatory system to measure blood pressure along the vessel and guide the delivery of catheters and stents.
The new wire supports iFR (instant wave-Free Ratio) measurements, the only resting index supported by randomized controlled outcome trials, as well as FFR (fractional flow reserve) measurements. It also integrates with the Philips IntraSight interventional applications platform, which can co-register iFR data onto the angiogram to precisely identify the parts of vessels requiring treatment.
Traditional pressure wires use a hollow metal tube (hypotube) to house the wiring that transmits the pressure information. Due to their thin walls, these wires can be challenging to manoeuvre and can sometimes kink, potentially becoming damaged during the procedure. OmniWire is the world’s first solid core pressure guidewire, using advanced conductive ribbons embedded in its outer polymer layer to communicate pressure information. The distal part of the wire is made from Nitinol, a super-elastic, durable material that is commonly used in non-diagnostic, interventional ‘workhorse’ guide wires. The proximal part of the wire is constructed from a highstrength cobalt alloy that provides the high durability required for complex and multi-vessel cases.
Commenting on the device, Dr. Jasvindar Singh, director of the catheterization lab at Barnes Jewish Hospital and associate professor at Washington University in St. Louis, U.S., who performed the first human case with OmniWire in the United States, said: “I have been very impressed with the handling of OmniWire, the new solid core design performed beautifully, and I was able to navigate the difficult case easily. We used iFR co-registration and found that the patient needed a stent. I was then able to perform the whole procedure working over OmniWire. This is truly an innovation in percutaneous coronary interventions.”
OmniWire has received clearance from the U.S. FDA and approval from the Japan Pharmaceuticals and Medical Devices Agency.
Read more
New biorubber glue can bond blood vessels, close wounds
, /in Product News /by 3wmediaMaterials scientists from Nanyang Technological University, Singapore have invented a new type of surgical glue that can bond blood vessels and close wounds, even when their surfaces are wet.
Named CaproGlu, it is activated by a low dose of ultraviolet light that cures it in seconds, turning it from a liquid glue into a solid but flexible biorubber – a biocompatible material that can be resorbed by the tissue after a few weeks.
Unlike current bio-adhesives – which need two chemicals to be mixed prior to use – the CaproGlu is a one-pot liquid gel solution that comes ready-to-use.
In a study published in Biomaterials in July they showed in animal experiments that blood vessels can be rejoined with just four stitches and a mesh wrapper dipped in CaproGlu, compared to the usual eight stitches that are required for a reliable and unobstructed join. The authors estimate that this will reduce surgery time by 25 per cent, as surgeons spend less time and effort stitching up blood vessels and tissues.
They also showed that CaproGlu can also be used to deliver local anaesthetics or pain relief medication to tissues in the body, which may be useful both during and post operation.
The adhesion strength of CaproGlu was compared to other commercial bioadhesives on the market and was found to be three to seven times stronger, and is on a par with the shear strength of collagen and muscle tissue found in the human body.
CaproGlu combines two ingredients into a single-component formulation that does not require additives. The first is polycaprolactone – a biodegradable polymer which has been approved by the United States Food and Drug Administration for specific applications used in the human body – and the second: diazirine, a light-sensitive molecule that can form strong bonds when activated.
The research team have filed for a provisional patent for the biorubber glue.
Read more
Biotronik’s a new injectable cardiac monitor reduces false positive readings
, /in Product News /by 3wmediaBiotronik has introduced a new injectable cardiac monitor (ICM). The BIOMONITOR IIIm is equipped with a unique algorithm that significantly reduces false positive atrial fibrillation (AF) detections due to ectopic beats.
Physicians can lose time reviewing these nonactionable episodes. Research shows that 52% of false positive AF episodes occur due to premature ectopic beats, which can be falsely detected as AF.
According to Biotronik, the new device can achieve a 72% reduction in false positives while maintaining 100% of AF-related sensitivity. It removes single ectopic beats out of the AF detection algorithm, enhancing diagnostic accuracy. This will make physicians’ workload more efficient.
These new features are supported by image quality comparable to those recorded on a gold-standard 12-lead ECG.
BIOMONITOR IIIm is also the industry leader in battery longevity with 5.5 years of continuous service, providing long-term post-ablation or cryptogenic stroke monitoring. It is also backed by the Patient App, which allows patients to include vital symptom data, providing physicians with symptom-rhythm correlation which strengthens diagnostic precision.
For more information, visit: www.biotronik.com/en-de/products/arrhythmiamonitoring/ biomonitorIIIm
Read more